Pharmaceuticals (Jan 2013)

Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges

  • John C. Burnett,
  • John J. Rossi,
  • Jiehua Zhou,
  • Ka-To Shum

DOI
https://doi.org/10.3390/ph6010085
Journal volume & issue
Vol. 6, no. 1
pp. 85 – 107

Abstract

Read online

RNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the development of safe and effective delivery systems. Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy. Therefore, in this review, we introduce the major hurdles in achieving efficient RNAi delivery and discuss the current advances in applying nanotechnology-based delivery systems to overcome the delivery hurdles of RNAi therapeutics. In particular, some representative examples of nanoparticle-based delivery formulations for targeted RNAi therapeutics are highlighted.

Keywords